New brain drug ITI-333 tested in healthy volunteers for first time
NCT ID NCT05470101
First seen Jun 26, 2026 · Last updated Jun 26, 2026 · Updated 1 time
Summary
This early-stage study tested a single dose of the experimental drug ITI-333 in 12 healthy adults. Researchers used brain scans to see how much of the drug attached to a specific receptor (5-HT2A) in the brain. They also checked safety, side effects, and how the drug moves through the body. The goal was to gather basic information, not to treat any disease.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
ITI-333
What this could lead to
If successful, this study could help determine the right dose for future trials of ITI-333 in conditions like psychiatric disorders.
What could go wrong
This is a very early, small study in only 12 healthy people. It is not designed to test if the drug works for any disease, and results may not predict effects in patients.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEALTHY VOLUNTEERS are added.
By submitting, you agree to our Terms of use
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Clinical Site 1
St Louis, Missouri, 63110, United States
-
Clinical Site 2
Creve Coeur, Missouri, 63141, United States